Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BV10

UPID:
ALG12_HUMAN

ALTERNATIVE NAMES:
Asparagine-linked glycosylation protein 12 homolog; Dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichyl-alpha-1,6-mannosyltransferase; Mannosyltransferase ALG12 homolog; Membrane protein SB87

ALTERNATIVE UPACC:
Q9BV10; A6PWM1; Q4KMH4; Q8NG10; Q96AA4

BACKGROUND:
Mannosyltransferase ALG12 homolog, known for its essential function in the glycosylation process, adds a crucial mannose residue to the dolichol-PP-oligosaccharide precursor. This enzyme's activity underscores its importance in the biosynthesis of glycoproteins.

THERAPEUTIC SIGNIFICANCE:
Its association with Congenital disorder of glycosylation 1G highlights the critical role of glycosylation in human health. Targeting the function of Mannosyltransferase ALG12 homolog offers a promising avenue for developing treatments for glycosylation-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.